Three Blood Tests, One Score: New LIP Tool Spots Sepsis Early and Predicts Outcomes

Sepsis remains one of medicine’s most elusive killers. It begins innocuously—a urinary infection, a chest cold, a small wound—but within hours the body’s response to infection can spiral into widespread inflammation, organ failure, and death. Every hour of delayed treatment measurably increases mortality, yet identifying which hospitalized patients with suspected infection are actually tipping into sepsis has stubbornly resisted decades of effort. Now, a large prospective study conducted across ten tertiary hospitals in China reports that a remarkably simple score built from just three routine blood tests—the LIP score, combining Lymphocyte count, INR, and Procalcitonin—can detect sepsis with accuracy that outperforms established screening tools, while also offering clues about a patient’s likely clinical course.

The study, published in BMC Medicine, enrolled 1,202 adults with suspected infection and systematically compared the LIP score against the existing arsenal of bedside and laboratory-based assessments, including SIRS criteria, qSOFA, SOFA, NEWS, and APACHE-II. The results were striking. At a cutoff of 3 points or more, the LIP score achieved an area under the receiver operating characteristic curve (AUROC) of 0.932, with a 95 percent confidence interval of 0.916 to 0.945. In practical terms, that means the score distinguished septic from non-septic patients with near-excellent discrimination. Its sensitivity reached 85.37 percent—meaning it caught the vast majority of true sepsis cases—while its specificity climbed to 94.83 percent, meaning it rarely raised false alarms. Statistically, it significantly outperformed every comparator score tested, with all comparisons yielding P values below 0.001.

What makes this performance notable is not just the numbers but the philosophy behind them. Rather than being mined from a database by machine learning and reverse-engineered afterward, the LIP score was constructed from pathophysiology—each component chosen because it captures a distinct biological axis of sepsis. The lymphocyte count reflects the immune system’s state: in sepsis, lymphocytes become depleted, a phenomenon linked to immunosuppression and the expansion of myeloid-derived suppressor cells that blunt the body’s defenses. The international normalized ratio, or INR, a standard measure of blood clotting tendency, captures the coagulation disturbances that accompany sepsis, from sepsis-induced coagulopathy to the life-threatening cascade of disseminated intravascular coagulation. Procalcitonin, a peptide precursor of the hormone calcitonin, rises sharply in bacterial infection and has long served as one of the most trusted biomarkers for distinguishing bacterial sepsis from non-infectious inflammation.

By combining these three markers, the score essentially triangulates sepsis from three directions at once: immune collapse, clotting dysfunction, and bacterial burden. Each component contributes points, and the total—ranging from 0 upward—signals the probability that a patient meets the Sepsis-3 definition, the current international consensus standard. This design choice matters clinically because all three tests are already ordered routinely in any hospital ward evaluating a febrile patient. No new assay, no specialized equipment, and no additional blood draw is required; the score can be computed from data that already exists in the patient’s chart, making it extraordinarily cheap and fast to deploy.

The study’s analytical rigor went well beyond a simple head-to-head comparison. The researchers used restricted cubic splines, a flexible statistical technique, to model the relationship between LIP scores and intensive care unit length of stay, uncovering a biphasic association—patients at both low and high ends of the score spectrum showed distinct patterns of ICU utilization. They also deployed advanced visualization methods, including Sankey and Chord diagrams, to map how patients flowed between risk strata, and SHAP (SHapley Additive exPlanations) analysis, a machine learning interpretability technique, to quantify how much each of the three components contributed to the score’s predictions. This blend of classical epidemiology and modern interpretability tools reflects a growing trend in critical care research: scores must not only work, but clinicians must understand why they work before trusting them with lives.

Prognostically, the picture was more nuanced. In predicting mortality, the LIP score surpassed the old SIRS criteria decisively (P < 0.001), confirming that the outdated systemic inflammatory response syndrome criteria—which many experts have long argued are too sensitive and too nonspecific—are inferior for risk stratification. However, LIP was outperformed by the National Early Warning Score (P = 0.031) and by SOFA (P < 0.001), while performing comparably to qSOFA (P = 0.28). This is an honest and important caveat: SOFA, which requires a fuller panel of physiological measurements, remains the gold standard for assessing organ dysfunction and predicting death. The LIP score is not positioned to replace it, but rather to serve as a rapid, early screening gate—flagging patients who then warrant full SOFA evaluation and aggressive intervention.

The study also explored the score’s role as an early-warning tool, and here the researchers offered a clever refinement. Using a simple threshold of 2 points or more, the LIP score achieved very high sensitivity of 94.58 percent—catching nearly every patient who would go on to develop sepsis—but specificity dropped to a limited 62.72 percent, meaning many flagged patients would be false positives. To solve this, the team tested a modified rule: instead of summing the total score, clinicians flag a patient if any two of the three components score at least 1 point each. This modification pushed specificity up to 83.14 percent, dramatically reducing false alarms while preserving the score’s ability to catch early cases. This kind of dual-threshold architecture—high sensitivity for initial screening, higher specificity for confirmation—mirrors how successful screening programs operate in other areas of medicine.

Beyond diagnosis and mortality, the researchers probed whether the LIP score could predict microbiological confirmation—whether blood cultures and other tests would actually identify a pathogen. Here the score performed modestly, on par with qSOFA, APACHE-II, and NEWS. That is a realistic limitation worth acknowledging: sepsis is a clinical syndrome, not a microbiological diagnosis, and many septic patients never yield a positive culture. A score that predicts clinical deterioration is arguably more valuable at the bedside than one that predicts culture results, but the modesty of this finding underscores that LIP is a clinical screening tool, not a substitute for microbiological workup.

The multicenter, prospective design strengthens the findings considerably. Prospective studies, in which data are collected according to a pre-specified protocol as patients are enrolled, are far less prone to the biases that plague retrospective analyses of electronic health records. Spanning ten tertiary hospitals across China, the study captured a geographically and demographically diverse patient population, and the authors report that all participants or their legally authorized representatives provided written informed consent, with ethics approval from the Medical Ethics Committee of Chongqing Emergency Medical Center. The research was supported by funding from the National Natural Science Foundation of China and several Chongqing regional science and health programs, and the authors declare no competing interests—an important transparency note given that sepsis biomarkers often intersect with commercial diagnostic interests.

Where does this leave the field? The authors conclude that the LIP score is a simple and efficient screening tool for sepsis in hospitalized patients, with good diagnostic performance at a cutoff of 3 or more and a close association with clinical outcomes. They also note preliminary evidence suggesting promise for emergency department use, though they are careful to state that further validation is needed before extending the score beyond hospitalized wards. Sepsis kills millions worldwide each year, and the Surviving Sepsis Campaign has long emphasized that early recognition is the single most impactful intervention. A tool that requires nothing more than three numbers already sitting in a patient’s chart—and that outperforms the scores clinicians have relied on for decades—could, if validated in broader and more diverse populations, become a genuinely transformative addition to the sepsis detection toolkit. For now, the LIP score stands as a compelling example of how pathophysiology-driven design, tested with modern statistical rigor, can yield clinical tools that are both scientifically elegant and immediately practical.

Subject of Research: Validation of the LIP score, a three-component blood-test tool for sepsis screening and prognosis

Article Title: The LIP score: a pathophysiology-driven tool for sepsis screening and prognosis—a multicenter prospective study

Article References: The LIP score: a pathophysiology-driven tool for sepsis screening and prognosis—a multicenter prospective study. (n.d.). https://doi.org/10.1186/s12916-026-05312-x

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05312-x

Keywords: sepsis, LIP score, procalcitonin, INR, lymphocyte count, diagnostic markers, screening, prognosis, SOFA, early warning, critical care, BMC Medicine